A randomized controlled double-blind study of rotigotine on neuropsychiatric symptoms in de novo PD.
Journal
NPJ Parkinson's disease
ISSN: 2373-8057
Titre abrégé: NPJ Parkinsons Dis
Pays: United States
ID NLM: 101675390
Informations de publication
Date de publication:
15 Dec 2020
15 Dec 2020
Historique:
received:
10
07
2020
accepted:
30
10
2020
entrez:
15
12
2020
pubmed:
16
12
2020
medline:
16
12
2020
Statut:
epublish
Résumé
Management of apathy, depression and anxiety in Parkinson's disease (PD) represents a challenge. Dopamine agonists have been suggested to be effective. This multicenter, randomized (1:1), double-blind study assessed the 6-month effect of rotigotine versus placebo on apathy, depression and anxiety in de novo PD. The primary outcome was the change of apathy, measured with the LARS. The secondary outcomes were the change in depression and anxiety, measured with BDI-2 and STAI-trait and state. Forty-eight drug-naive PD patients were included. The primary outcome was not reached, with a surprisingly high placebo effect on apathy (60%). There was no significant difference in the change of depression at 6 months between rotigotine and placebo. Trait-anxiety was significantly improved by rotigotine compared to placebo (p = 0.04). Compared to placebo, low dose rotigotine significantly improved trait anxiety, but not apathy and depression. The major placebo effect on apathy points towards the importance of a multidisciplinary and tight follow-up in the management of neuropsychiatric symptoms.
Identifiants
pubmed: 33319786
doi: 10.1038/s41531-020-00142-x
pii: 10.1038/s41531-020-00142-x
pmc: PMC7738499
doi:
Types de publication
Journal Article
Langues
eng
Pagination
41Références
Parkinsonism Relat Disord. 2013 Jul;19(7):660-5
pubmed: 23557594
J Neurol. 2010 Feb;257(2):217-23
pubmed: 19705051
Lancet Neurol. 2015 May;14(5):518-31
pubmed: 25895932
Neuropsychologia. 2002;40(13):2257-67
pubmed: 12417456
Lancet Neurol. 2019 Aug;18(8):748-759
pubmed: 31229470
Brain. 2010 Apr;133(Pt 4):1111-27
pubmed: 20237128
J Neurol Neurosurg Psychiatry. 2006 May;77(5):579-84
pubmed: 16614016
Mov Disord. 2008 Nov 15;23(15):2129-70
pubmed: 19025984
Funct Neurol. 2018 Jan/Mar;33(1):31-35
pubmed: 29633694
Mov Disord. 2011 Oct;26 Suppl 3:S42-80
pubmed: 22021174
Int J Neurosci. 2018 Apr;128(4):369-375
pubmed: 29249180
J Neurol. 2018 Apr;265(4):764-773
pubmed: 29392459
Brain. 2016 Sep;139(Pt 9):2486-502
pubmed: 27538418
J Parkinsons Dis. 2015;5(3):659-67
pubmed: 26406147
BMC Neurol. 2016 Jun 07;16:90
pubmed: 27267880
J Neurol Neurosurg Psychiatry. 2019 Mar;90(3):302-312
pubmed: 30366958
Mov Disord. 2015 May;30(6):759-69
pubmed: 25787145
J Neuropsychiatry Clin Neurosci. 1992 Spring;4(2):134-9
pubmed: 1627973
Mov Disord. 2015 Jun;30(7):919-27
pubmed: 25737166
Brain. 2013 May;136(Pt 5):1568-77
pubmed: 23543483
Eur J Neurol. 2015 Oct;22(10):1400-7
pubmed: 26095948
J Neurol Sci. 2011 Nov 15;310(1-2):216-9
pubmed: 21689829
J Parkinsons Dis. 2016;6(1):267-77
pubmed: 27003781
Mov Disord. 2016 Aug;31(8):1103-13
pubmed: 27041545
J Pers Assess. 1996 Dec;67(3):588-97
pubmed: 8991972
Neurology. 2000 Dec 12;55(11):1621-6
pubmed: 11113214
Lancet Neurol. 2010 Jun;9(6):573-80
pubmed: 20452823
Mov Disord. 2015 Feb;30(2):121-7
pubmed: 25370355
J Parkinsons Dis. 2015;5(3):625-36
pubmed: 25870025
Lancet Neurol. 2007 Jun;6(6):513-20
pubmed: 17509486
Science. 2001 Aug 10;293(5532):1164-6
pubmed: 11498597
Neurodegener Dis Manag. 2018 Aug;8(4):267-282
pubmed: 30040024
J Neurol Neurosurg Psychiatry. 2009 Aug;80(8):928-30
pubmed: 19608786
J Neurol Neurosurg Psychiatry. 2014 Jun;85(6):668-74
pubmed: 24218528
Brain. 2005 Jun;128(Pt 6):1314-22
pubmed: 15716302
Rev Neurol (Paris). 2009 Nov;165(11):845-56
pubmed: 19683776
Parkinsonism Relat Disord. 2017 Oct;43:49-55
pubmed: 28711192
Mov Disord. 2015 Apr 15;30(5):705-13
pubmed: 25809278
Parkinsonism Relat Disord. 2017 Nov;44:28-32
pubmed: 28844367
Age Ageing. 1997 Sep;26(5):353-7
pubmed: 9351479
PLoS Med. 2008 Feb;5(2):e45
pubmed: 18303940
Mov Disord. 2014 Dec;29(14):1796-801
pubmed: 25370724